Instituto Oncológico FALP (Fundación Arturo Lopez Perez)
Instituto Oncológico FALP (Fundación Arturo Lopez Perez)
José Manuel Infante 805, Providencia, Región Metropolitana, Santiago
Select an option
I am a doctor
I am a sponsor
Open studies
Advanced tumors
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) - MK-3475-587 - Merck Sharp & Dohme Corp.See more
Bladder Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) - Merck Sharp & Dohme LLCSee more
Esophageal cancer
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) - DESTINY-Gastric04 - AstraZenecaSee more
Gastric cancer
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) - DESTINY-Gastric04 - AstraZenecaSee more
Gastroesophageal cancer
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) - DESTINY-Gastric04 - AstraZenecaSee more
Lung cancer
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003) - KEYVIBE-003 - Merck Sharp & Dohme Corp.See more
Prostate cancer
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641) - MK-3475-641 - Merck Sharp & Dohme Corp.See more
Solid tumors
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) - MK-3475-587 - Merck Sharp & Dohme Corp.See more
Urothelial cancer
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 - KEYNOTE-D78 - Seagen Inc.See more
